Quantum Biopharma Ltd. amended its foreign private issuer report through Amendment No. 1, with registration reference 333-276264. The initial report remains effective except where the amendment changes it, and the amendment is treated as part of the initial report for investors reviewing the company’s disclosed record.
Key Highlights
- Quantum Biopharma filed Amendment No. 1 to its Foreign Private Issuer Report on Form 6-K.
- Quantum Biopharma identified Form 20-F as the annual-report framework it uses.
- The amendment is treated as part of the initial report from the date it was furnished, except where later reports supersede it.
Quantum Biopharma Ltd. (NASDAQ: QNTM) amended its foreign private issuer report through Amendment No. 1, while stating that the initial report remains unchanged except for the matters covered by the amendment. The record carries reference 333-276264.
Amendment No. 1 Updates Existing Report
Quantum Biopharma identifies itself as a foreign private issuer and marks Form 20-F as the annual-report framework it files. Form 40-F is not selected. The report names Quantum Biopharma Ltd. and states that the amendment is deemed part of the Initial Report.
Initial Report Remains in Effect
The amended material is treated as part of the initial report from the date that report was furnished. Quantum Biopharma also states that later reports can supersede the incorporated material. The document is signed on behalf of Quantum Biopharma Ltd. by an authorised representative under the Securities Exchange Act of 1934.
FAQs
Q: What did Quantum Biopharma change in its foreign private issuer report?
A: Quantum Biopharma issued Amendment No. 1 to its foreign private issuer report. The initial report remains unchanged except for the matters addressed by the amendment.
Q: What report framework does Quantum Biopharma use?
A: Quantum Biopharma identifies Form 20-F as the annual-report framework selected in the filing. The filing leaves Form 40-F unchecked, so it does not select Form 40-F as the company’s annual-report form.
Q: What is the significance of reference 333-276264?
A: Reference 333-276264 appears in Quantum Biopharma’s amended reporting record. The amendment is treated as part of the initial report from its furnishing date.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.